SCHEMBL23988634

SCHEMBL23988634

C=CC(=O)Nc1ccc(NS(=O)(=O)c2ccc(C(C)C)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 3/20 0.58
LMNA P02545 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
ALDH1A1 P00352 2/20 0.56
MAPT P10636 1/20 0.56
PKM P14618 1/20 0.56
GHSR Q92847 1/20 0.56
POLB P06746 4/20 0.52
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA9 Q16790 1/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
PGR P06401 1/20 0.49
KDM4E B2RXH2 1/20 0.49
F13A1 P00488 1/20 0.48
TGM1 P22735 1/20 0.48
TRIM24 O15164 1/20 0.47
BRD1 O95696 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20885056 0.87 TGM2 (0.63) TGM2LMNAALDH1A1MAPTPKM
SCHEMBL23988635 0.87 BTK (0.52) TGM2LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL1381808 0.85 TGM2 (0.65) TGM2LMNASMN1; SMN2CA12CA1
SCHEMBL23988607 0.85 PGR (0.54) TGM2ALDH1A1MAPTPKMPOLB
SCHEMBL3821674 0.85 ALDH1A1 (0.71) TGM2LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL14394819 0.85 CES1 (0.65) TGM2LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL9568792 0.85 ALDH1A1 (0.71) TGM2LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL3820009 0.83 TGM2 (0.67) TGM2SMN1; SMN2ALDH1A1PKMPOLB
SCHEMBL14394824 0.82 ALDH1A1 (0.65) TGM2LMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL9568604 0.81 TGM2 (0.64) TGM2ALDH1A1PKMPOLBCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11155556-B2 Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11155556-B2 Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders PI4KA, PIK3CA, PI4KB TGM2 2619/4885LMNA 2983/4885SMN1; SMN2 1752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.